Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest HCV Stories

2013-01-03 08:25:52

SAN DIEGO, Jan. 3, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, disclosed today that it has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) that requests permission to initiate a clinical feasibility study of Hepatitis-C (HCV) infected individuals enrolled to receive Hemopurifier®...

2013-01-02 16:22:23

WORCESTER, Mass., Jan. 2, 2013 /PRNewswire/ -- Microbiotix, Inc., a privately-held, clinical stage biopharmaceutical company engaged in the discovery and development of novel small molecule anti-infective drugs, announced today that it has entered into an exclusive licensing agreement with Merck, known as MSD outside the United States and Canada. As part of this agreement, Microbiotix gains worldwide rights to develop, manufacture and commercialize MBX-700 and MBX-701 (formerly SCH 900942...

2012-12-03 08:26:26

SAN DIEGO, Dec. 3, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, today announced the initiation of a compassionate-use clinical program to treat individuals infected with Hepatitis C virus (HCV). The compassionate-use program, which has been approved by the Institutional Review Board at the Medanta Medicity Institute (Medicity), will...

2012-11-27 12:29:02

Summit on HIV and Viral Hepatitis Charts Priorities to Accelerate Testing, Reduce Disparities in Care WASHINGTON, Nov. 27, 2012 /PRNewswire-USNewswire/ -- As the countdown to implementation of the Affordable Care Act begins in earnest, experts on the front lines in fighting viral hepatitis and HIV/AIDS issued this harsh assessment regarding escalating levels of hepatitis C virus (HCV) infection: unless policymakers require insurers to cover the costs of screening everyone at potential...

2012-11-15 08:29:59

Merck's hepatitis C treatment receives prestigious Innovative Product Award KIRKLAND, QC, Nov. 15, 2012 /CNW/ - Merck is proud to announce that VICTRELIS(TM) (boceprevir), a first-in-class oral hepatitis C virus (HCV) protease inhibitor for the treatment of chronic hepatitis C (CHC) genotype 1 infection, received the Prix Galien Canada 2012 - Innovative Product Award. The most prestigious award in the field of Canadian pharmaceutical research and innovation,(1) this annual honour is...

2012-11-10 12:21:24

BOSTON and RIDGEFIELD, Conn., Nov. 10, 2012 /PRNewswire/ -- Final Phase 2b data from Boehringer Ingelheim's interferon (IFN)-free Phase 2b SOUND-C2 study showed that up to 85 percent of genotype 1b (GT1b) hepatitis C (HCV) patients achieved sustained virologic response (SVR or viral cure) 12 and 24 weeks after the end of treatment with the investigational treatment regimen of faldaprevir (BI 201335) and BI 207127, in combination with ribavirin (RBV). A viral cure was achieved for 69 percent...

2012-11-10 08:21:59

MENLO PARK, Calif., Nov. 10, 2012 /PRNewswire/ -- 3-V Biosciences, Inc., announced today that preclinical data for its novel fatty acid synthase (FASN) inhibitors for the treatment of chronic hepatitis C virus (HCV) infection will be presented at the 63(rd) Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting®) being held November 9-13 in Boston, Massachusetts. (Logo: http://photos.prnewswire.com/prnh/20121001/LA83573LOGO) "New, potent...

2012-11-10 08:21:53

BOSTON, Nov. 10, 2012 /PRNewswire/ -- The American Association for the Study of Liver Diseases (www.aasld.org) today announced a new initiative to provide ongoing education and training to healthcare professionals treating liver diseases. AASLD Curriculum & Training (ACT) will deliver reliable information and instruction for the treatment of patients with a variety of liver diseases including viral hepatitis. The first program to be released, ACT on HCV, A Practical Introduction to...

2012-11-10 08:21:37

BOSTON, Massachusetts, November 10, 2012 /PRNewswire/ -- - Study presented at American Association for the Study of Liver Diseases 2012 shows high sustained virological response (SVR) in HCV/HIV co-infected patients receiving INCIVO(R) (telaprevir)-based regimen - Janssen Infectious Diseases-Diagnostics BVBA (Janssen) today presented results from a new phase 2 study which shows that an INCIVO(R) (telaprevir)-based regimen was effective in...

2012-11-09 12:26:11

NEW HAVEN, Conn., Nov. 9, 2012 /PRNewswire/ -- Event: HCV Connection Media Briefing Date: Monday, November 12 Time: 7:45 a.m. Eastern Standard Time Where: Sheraton Boston Hotel; 39 Dalton Street, Boston, MA 02199; Also available by Webcast (link will be provided upon...


Latest HCV Reference Libraries

11_9e88d15808b8ecc3fcbbdfcf4ae75786
2011-01-20 19:23:30

Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. It consists of a core of genetic material surrounded by an icosahedra protective shell of protein. The genome consists of a single open reading frame that is 9600 nucleotide bases long. HCV replication takes several steps. It primarily replicates in the hepatocytes of the liver. It can also reproduce in peripheral blood mononuclear cells. There is a wide variety of genotypes and...

More Articles (1 articles) »